Russia authorizes Pfizer to conduct clinical trials for its experimental COVID-19 drug named Paxlovid, where the trials will continue until March 2023.
Russia authorizes Pfizer to conduct clinical trials for its experimental COVID-19 drug named Paxlovid, which will continue until March 2023.